

Performance in Delivering Report Qtr 3 Oct- Dec 2018

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
15/NW/0586	184456	CARD 4754: Non-interventional study on Edoxaban treatment in routine clinical practice for patients with non valvular atrial fibrillation	Number Agreed	20	20	Date Agreed	12/11/2016	37	21/01/2018	37	Recruitment Finished	
16/LO/1810	209789	UTX-TGR-304: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)	Number Agreed	3	3	Date Agreed	19/10/2016	0	13/02/2018	0	Recruitment Finished	Ethical concerns regarding radiation dose voiced by radiology professionals, followed by contracting delays with sponsors.(at least1/12). Recruitment then closed early.
05/Q1206/168	32077	Prostate Adenocarcinoma: TransCutaneous Hormones. A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH analogues in prostate cancer.	Number Agreed	10	10	Date Agreed	03/10/2011	9	31/03/2018	9	Recruitment Finished	Closed according to schedule
16/EM/0194	194984	DERM 5311Effectiveness of an image analysing algorithm to diagnose melanoma compared to gold standard histological determination	Number Agreed	23	23	Date Agreed	30/09/2018	23	29/06/2018	23	Recruitment Finished	Recruitment was originally extended from 31/05/18 to 30/09/18, however Sponsor closed recruitment 29/06/18
17/LO/0794	223700	RHCF - A 52-week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis who are Biologic Disease-Modifying Anti-Rheumatic Drug Naive	Number Agreed	2	2	Date Agreed	30/04/2018	2	30/04/2018	2	Recruitment Finished	
17/LO/1147	222154	ECZTRA 2 - Tralokinumab in moderate-severe AD -1326	Number Agreed	6	6	Date Agreed	31/05/2018	7	26/04/2018	7	Recruitment Finished	Due to study recruitment numbers being met earlier
16/EM/0384	182787	BMS Augustus - "An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and ACS or PCI	Number Agreed	6	6	Date Agreed	31/05/2018	1	10/04/2018	1	Recruitment Finished	Due to study recruitment numbers being met earlier
17/EE/0079	220827	CL010_168 A Randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of CCX168 in pts with anti-neutrophil cytoplasmic antibody (ANCA)- Associated Vasculitis	Number Agreed	2	2	Date Agreed	31/12/2018	0	04/07/2018	0	Recruitment Finished	Due to study recruitment numbers being met earlier
18/YH/0012	237184	ECZTRA 3 (ECZema TRAlokinumab trial no. 3)	Number Agreed	6	6	Date Agreed	18/08/2018	4	12/10/2018	4	Recruitment Finished	PI taken long term sickness absence, which affected reaching recruitment target
16/EM/0193	190690	The Dal-GenE trial (CARD 4843) - A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS)	Number Agreed	6	6	Date Agreed	31/10/2018	7	12/11/2018	7	Recruitment Finished	
18/SC/0210	239572	EFFICACY AND SAFETY OF PF-04965842 200 MG AND 100 MG QD MONOTHERAPY IN SUBJECTS WITH AD	Number Agreed	1	1	Date Agreed	26/11/2018	0	26/11/2018	0	Recruitment Finished	Difficult to recruit to
16/LO/1822	212944	VICTORIA - A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejec	Number Agreed	10	10	Date Agreed	31/12/2018	11	31/12/2018	11	Recruitment Finished	